In the News

The challenges faced by the life sciences industry are well documented – fall-off in NDA’s, more complex clinical trial programs, and overall increasing costs with diminishing successes. With such widelypublished, consistent depictions of these challenges, one would expect the industry to look for more opportunities to change their approach to drug development.